vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $85.8M, roughly 1.0× Xeris Biopharma Holdings, Inc.). LXP Industrial Trust runs the higher net margin — 33.2% vs 12.9%, a 20.3% gap on every dollar of revenue. On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs -14.0%). Over the past eight quarters, Xeris Biopharma Holdings, Inc.'s revenue compounded faster (45.3% CAGR vs 0.3%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
LXP vs XERS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $85.8M |
| Net Profit | $28.8M | $11.1M |
| Gross Margin | 81.5% | — |
| Operating Margin | 34.6% | 19.5% |
| Net Margin | 33.2% | 12.9% |
| Revenue YoY | -14.0% | 42.8% |
| Net Profit YoY | — | 316.7% |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $85.8M | ||
| Q3 25 | $86.9M | $74.4M | ||
| Q2 25 | $87.7M | $71.5M | ||
| Q1 25 | $88.9M | $60.1M | ||
| Q4 24 | $100.9M | $60.1M | ||
| Q3 24 | $85.6M | $54.3M | ||
| Q2 24 | $85.8M | $48.1M | ||
| Q1 24 | $86.3M | $40.6M |
| Q4 25 | $28.8M | $11.1M | ||
| Q3 25 | $36.3M | $621.0K | ||
| Q2 25 | $29.1M | $-1.9M | ||
| Q1 25 | $19.0M | $-9.2M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $6.3M | $-15.7M | ||
| Q2 24 | $5.4M | $-15.0M | ||
| Q1 24 | $-269.0K | $-19.0M |
| Q4 25 | 81.5% | — | ||
| Q3 25 | 82.3% | — | ||
| Q2 25 | 81.9% | — | ||
| Q1 25 | 80.7% | — | ||
| Q4 24 | 85.3% | — | ||
| Q3 24 | 82.5% | — | ||
| Q2 24 | 82.0% | — | ||
| Q1 24 | 82.4% | — |
| Q4 25 | 34.6% | 19.5% | ||
| Q3 25 | 50.4% | 9.0% | ||
| Q2 25 | 33.7% | 6.3% | ||
| Q1 25 | 21.8% | -5.1% | ||
| Q4 24 | — | 2.8% | ||
| Q3 24 | 7.9% | -23.8% | ||
| Q2 24 | 6.9% | -17.0% | ||
| Q1 24 | 1.0% | -35.1% |
| Q4 25 | 33.2% | 12.9% | ||
| Q3 25 | 41.7% | 0.8% | ||
| Q2 25 | 33.2% | -2.7% | ||
| Q1 25 | 21.4% | -15.3% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | 7.4% | -29.0% | ||
| Q2 24 | 6.3% | -31.2% | ||
| Q1 24 | -0.3% | -46.7% |
| Q4 25 | — | $0.07 | ||
| Q3 25 | $0.12 | $0.00 | ||
| Q2 25 | $0.09 | $-0.01 | ||
| Q1 25 | $0.06 | $-0.06 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.02 | $-0.11 | ||
| Q2 24 | $0.01 | $-0.10 | ||
| Q1 24 | $-0.01 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $111.0M |
| Total DebtLower is stronger | $1.4B | $220.3M |
| Stockholders' EquityBook value | $2.0B | $13.7M |
| Total Assets | $3.5B | $383.5M |
| Debt / EquityLower = less leverage | 0.66× | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $111.0M | ||
| Q3 25 | $229.7M | $91.6M | ||
| Q2 25 | $71.0M | $59.3M | ||
| Q1 25 | $70.9M | $58.4M | ||
| Q4 24 | $101.8M | $71.6M | ||
| Q3 24 | $55.0M | $69.4M | ||
| Q2 24 | $48.7M | $77.6M | ||
| Q1 24 | $293.8M | $87.4M |
| Q4 25 | $1.4B | $220.3M | ||
| Q3 25 | $1.5B | $219.5M | ||
| Q2 25 | $1.5B | $218.6M | ||
| Q1 25 | $1.5B | $229.8M | ||
| Q4 24 | $1.6B | $232.1M | ||
| Q3 24 | — | $216.2M | ||
| Q2 24 | — | $230.5M | ||
| Q1 24 | — | $229.7M |
| Q4 25 | $2.0B | $13.7M | ||
| Q3 25 | $2.1B | $-861.0K | ||
| Q2 25 | $2.1B | $-19.3M | ||
| Q1 25 | $2.1B | $-35.1M | ||
| Q4 24 | $2.1B | $-29.6M | ||
| Q3 24 | $2.1B | $-28.3M | ||
| Q2 24 | $2.1B | $-19.3M | ||
| Q1 24 | $2.2B | $-9.2M |
| Q4 25 | $3.5B | $383.5M | ||
| Q3 25 | $3.7B | $370.2M | ||
| Q2 25 | $3.7B | $334.7M | ||
| Q1 25 | $3.8B | $315.5M | ||
| Q4 24 | $3.8B | $323.1M | ||
| Q3 24 | $3.9B | $321.1M | ||
| Q2 24 | $3.9B | $331.7M | ||
| Q1 24 | $4.2B | $336.6M |
| Q4 25 | 0.66× | 16.10× | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $20.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 6.56× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $20.0M | ||
| Q3 25 | $63.5M | $18.4M | ||
| Q2 25 | $44.3M | $182.0K | ||
| Q1 25 | $39.0M | $-10.0M | ||
| Q4 24 | $211.2M | $2.0M | ||
| Q3 24 | $64.6M | $-8.3M | ||
| Q2 24 | $38.5M | $-10.3M | ||
| Q1 24 | $38.9M | $-20.3M |
| Q4 25 | 6.56× | 1.81× | ||
| Q3 25 | 1.75× | 29.68× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LXP
Segment breakdown not available.
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
